0001437749-16-042923.txt : 20161205
0001437749-16-042923.hdr.sgml : 20161205
20161205163101
ACCESSION NUMBER: 0001437749-16-042923
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161201
FILED AS OF DATE: 20161205
DATE AS OF CHANGE: 20161205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oxford Immunotec Global PLC
CENTRAL INDEX KEY: 0001586049
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
BUSINESS PHONE: 44 01235 442780
MAIL ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wrighton-Smith Peter
CENTRAL INDEX KEY: 0001592286
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36200
FILM NUMBER: 162034151
MAIL ADDRESS:
STREET 1: C/O OXFORD IMMUNOTEC GLOBAL PLC
STREET 2: 94C INNOVATION DRIVE
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
4
1
rdgdoc.xml
FORM 4
X0306
4
2016-12-01
0001586049
Oxford Immunotec Global PLC
OXFD
0001592286
Wrighton-Smith Peter
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE
X0
OX14 4RZ
UNITED KINGDOM
1
1
Chief Executive Officer
Ordinary Shares
2016-12-01
4
M
0
19925
0.81
A
504122
D
Ordinary Shares
2016-12-01
4
S
0
60808
15
D
443314
D
Ordinary Shares
2016-12-02
4
M
0
1000
0.81
A
444314
D
Ordinary Shares
2016-12-02
4
S
0
1000
15
D
443314
D
Stock Option (Right to Buy)
0.81
2016-12-01
4
M
0
19925
0
D
2020-02-17
Ordinary Shares
19925
110630
D
Stock Option (Rights to Buy)
0.81
2016-12-02
4
M
0
1000
0
D
2020-02-17
Ordinary Shares
1000
109630
D
The original exercise price of these options was priced in GBP at GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
The price reported for the sales on December 1, 2016 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.03 per share, inclusive. The reporting person undertakes to provide to Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.
/s/ Elizabeth M. Keiley, as Attorney-in-Fact
2016-12-05